Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies

Stock Information for Crescent Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescent Biopharma Inc.

Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
Aptinyx to Present at the SVB Securities Global Biopharma Conference
Preclinical Data from Aptinyx's NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.